All data are based on the daily closing price as of December 24, 2024
m
Medigen Vaccine Biologics
6547.TWO
1.12 USD
-0.01
-0.88%
Overview
Last close
1.12 usd
Market cap
368.38M usd
52 week high
2.43 usd
52 week low
1.05 usd
Target price
3.46 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
19.3232
Price/Book Value
3.1558
Enterprise Value
327.36M usd
EV/Revenue
16.515
EV/EBITDA
35.9795
Key financials
Revenue TTM
19.07M usd
Gross Profit TTM
-6.50M usd
EBITDA TTM
-19.11M usd
Earnings per Share
-0.06 usd
Dividend
N/A usd
Total assets
4.31B usd
Net debt
-40.19M usd
About
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.